The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Jan. 22, 2018
Applicant:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai, CN;

Inventors:

Jie Zhao, Shanghai, CN;

Honghai Gao, Shanghai, CN;

Jinlin Guo, Shanghai, CN;

Wei Dang, Shanghai, CN;

Lingqiao Zhu, Shanghai, CN;

Chenghai Zhang, Shanghai, CN;

Le Zhao, Shanghai, CN;

Jianhe Chen, Shanghai, CN;

Haomin Huang, Shanghai, CN;

Zhenping Zhu, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07H 21/04 (2006.01); C12P 21/06 (2006.01); C12N 15/87 (2006.01); C12N 1/20 (2006.01); C12N 15/74 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.


Find Patent Forward Citations

Loading…